InsiderTrades.com logo
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.
Anish Bhatnagar net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anish Bhatnagar Biography and Net Worth

CEO of Soleno Therapeutics
Dr. Bhatnagar was appointed as our Chief Executive Officer in February 2014. Prior to that, he served as our President and Chief Operating Officer. Dr. Bhatnagar joined us in 2006, and has held positions of increasing responsibility since then. Dr. Bhatnagar is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.

What is Anish Bhatnagar's net worth?

The estimated net worth of Anish Bhatnagar is at least $32.51 million as of October 1st, 2024. Dr. Bhatnagar owns 719,553 shares of Soleno Therapeutics stock worth more than $32,509,405 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Bhatnagar may own. Additionally, Dr. Bhatnagar receives an annual salary of $1,060,000.00 as CEO at Soleno Therapeutics. Learn More about Anish Bhatnagar's net worth.

How old is Anish Bhatnagar?

Dr. Bhatnagar is currently 54 years old. There are 5 older executives and no younger executives at Soleno Therapeutics. Learn More on Anish Bhatnagar's age.

What is Anish Bhatnagar's salary?

As the CEO of Soleno Therapeutics, Inc., Dr. Bhatnagar earns $1,060,000.00 per year. Learn More on Anish Bhatnagar's salary.

How do I contact Anish Bhatnagar?

The corporate mailing address for Dr. Bhatnagar and other Soleno Therapeutics executives is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. Soleno Therapeutics can also be reached via phone at (650) 213-8444 and via email at [email protected]. Learn More on Anish Bhatnagar's contact information.

Has Anish Bhatnagar been buying or selling shares of Soleno Therapeutics?

During the last ninety days, Anish Bhatnagar has sold $1,069,319.19 in shares of Soleno Therapeutics stock. Most recently, Bhatnagar Anish sold 21,633 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a transaction totalling $1,069,319.19. Following the completion of the sale, the chief executive officer now directly owns 719,553 shares of the company's stock, valued at $35,567,504.79. Learn More on Anish Bhatnagar's trading history.

Who are Soleno Therapeutics' active insiders?

Soleno Therapeutics' insider roster includes Anish Bhatnagar (CEO), James Mackaness (CFO), and Jack Schuler (Major Shareholder). Learn More on Soleno Therapeutics' active insiders.

Are insiders buying or selling shares of Soleno Therapeutics?

In the last twelve months, insiders at the sold shares 20 times. They sold a total of 1,579,354 shares worth more than $75,448,230.75. The most recent insider tranaction occured on October, 1st when insider Kristen Yen sold 3,108 shares worth more than $153,628.44. Insiders at Soleno Therapeutics own 12.3% of the company. Learn More about insider trades at Soleno Therapeutics.

Information on this page was last updated on 10/1/2024.

Anish Bhatnagar Insider Trading History at Soleno Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2024Sell21,633$49.43$1,069,319.19719,553View SEC Filing Icon  
8/28/2024Sell56,613$47.58$2,693,646.54799,577View SEC Filing Icon  
8/5/2024Sell58,213$45.77$2,664,409.01925,321View SEC Filing Icon  
7/1/2024Sell19,256$41.54$799,894.24133,534View SEC Filing Icon  
4/1/2024Sell18,980$41.34$784,633.20152,790View SEC Filing Icon  
1/25/2024Sell2,527$48.30$122,054.10171,770View SEC Filing Icon  
12/11/2023Sell93,408$35.67$3,331,863.3624,297View SEC Filing Icon  
11/30/2023Sell27,716$28.65$794,063.40108,062View SEC Filing Icon  
11/28/2023Sell25,678$27.12$696,387.36163,605View SEC Filing Icon  
1/21/2022Sell39,033$0.37$14,442.21View SEC Filing Icon  
8/19/2016Buy10,000$0.96$9,600.0083,419View SEC Filing Icon  
5/13/2016Buy5,000$1.15$5,750.0073,419View SEC Filing Icon  
See Full Table

Anish Bhatnagar Buying and Selling Activity at Soleno Therapeutics

This chart shows Bhatnagar Anish's buying and selling at Soleno Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Soleno Therapeutics Company Overview

Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More

Today's Range

Now: $45.18
Low: $44.19
High: $46.57

50 Day Range

MA: $52.93
Low: $45.18
High: $59.18

2 Week Range

Now: $45.18
Low: $35.70
High: $60.92

Volume

1,282,833 shs

Average Volume

494,505 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.